Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

8.75USD
16 Feb 2018
Change (% chg)

$-0.30 (-3.31%)
Prev Close
$9.05
Open
$9.05
Day's High
$9.20
Day's Low
$8.75
Volume
534,007
Avg. Vol
417,546
52-wk High
$9.50
52-wk Low
$1.50

Select another date:

Mon, Jan 29 2018

BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001

* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY

BRIEF-Henry Ji Reports 5.9 Pct Passive Stake In Sorrento Therapeutics

* HENRY JI REPORTS 5.9 PERCENT PASSIVE STAKE IN SORRENTO THERAPEUTICS INC AS OF JANUARY 21, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2netHja) Further company coverage:

BRIEF-Sorrento Therapeutics Enteres Into Securities Purchase Agreement

* SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING

BRIEF-Sorrento Therapeutics files for mixed shelf of upto $350 mln

* Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​ Source text: [http://bit.ly/2yLg1nW] Further company coverage:

BRIEF-Sorrento Therapeutics- ‍Terminated​ deal with Semnur Pharma to purchase all its issued and outstanding equity

* Sorrento Therapeutics - ‍ co, unit Semnur Pharmaceuticals terminated​ deal by which unit would, purchase all of issued and outstanding equity of Semnur Source text: (http://bit.ly/2xYZewg) Further company coverage:

BRIEF-Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​

* Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​ Source text: (http://bit.ly/2xTIxlX) Further company coverage:

BRIEF-FDA acknowledges receipt of Sorrento Therapeutics Inc's NDA for Ztlido

* Fda acknowledges receipt of Sorrento Therapeutics Inc, NDA for Ztlido; PDUFA date set for February 28, 2018

BRIEF-Sorrento Therapeutics submits NDA for Ztlido

* Sorrento Therapeutics Inc submits NDA for Ztlido next-generation lidocaine patch

Select another date: